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Introduction: Recurrent hypersomnia (RH) is a rare disorder without established treatment.
Methods: We report 2 RH medication-responsive cases with typical characteristics of
Kleine–Levin syndrome (KLS).
Case-reports: A 10 y.o. girl and a 14 y.o. boy presented with sudden sleepiness for 3–9 days
(every 2–3 weeks). Physical examination, brain images and blood tests were normal.
Polysomnographic ﬁndings were heterogenous, including disrupted sleep architecture.
MSLTs revealed 2–3 SOREMPs and short sleep latency. Carbamazepine rendered girl's sleep
normalization, while risperidone normalized boy's sleep cycles.
Conclusions: Facing the absence of clinical trials in RH, reports of responsive cases are the
available therapeutic evidence.
& 2015 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recurrent hypersomnia (RH) is a rare disorder that generally
affects teenagers and is characterized by episodes of exces-
sive sleep lasting up to several days, when patients sleep
almost all day and rise only to eat and void. When associated
with behavioral or cognitive disturbances, compulsive eating
and hypersexuality it is called Kleine–Levin syndrome (KLS)
[1–3].ep. Production and Hosti
licenses/by-nc-nd/4.0/).
Medicina (UPF), R. Teixe
C.M. Forcelini).
an Association of Sleep.Due to its distinctive clinical characteristics, KLS is usually
differentiated from other causes of hypersomnolence, like
narcolepsy, idiopathic hypersomnia and depression, but
polysomnography is required for excluding sleep disorder
breathing [3]. Neuroimage and other ancillary tests may be
necessary for assessing other clinical and neurological
conditions.
The cause of KLS is not established, but autoimmune and
genetic factors are suspected [4–6]. Infections, fever, trauma,ng by Elsevier B.V. This is an open access article under the CC BY-
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S l e e p S c i e n c e 8 ( 2 0 1 5 ) 1 0 0 – 1 0 2 101and stress may trigger the disease. Although clinical and
neurophysiological aspects have already been characterized
[1–3,7], the pathophysiology of KLS is still obscure. Hypotha-
lamic dysfunction was suggested because of the ﬁndings of
low hypocretin-1 levels in central system ﬂuid (CSF) during
symptomatic episodes [8] and decreased thalamic blood ﬂow
demonstrated during sleep attacks [9], although thalamic [10]
and widespread brain hypermetabolism were recently
described [11].
There is no clinical trial evaluating drugs for the treatment
of RH [12]. The only available therapeutic evidence is
obtained from case reports and series of cases [1,2,5,13–16].
In this setting, we report the cases of RH patients with typical
characteristics of KLS, with a complete and sustained
response to pharmacological treatment.2. Methods
Two RH patients who are accompanied for years by the same
physician (CMF), in Passo Fundo – RS, Brazil, have their cases
reported. The written consent was previously obtained from
patients for publication purpose.
2.1. Case reportsT
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bCase 1: a 10 y.o. Afro-Brazilian girl began with sudden
sleepiness that lasted 7 days, when she woke for only 1 h a
day, with confusion and greedy hunger. The attacks
recurred every 2 weeks, resulting in weight gain. Between
the attacks she slept normally and forgot the episodes.
Physical examination, brain MRI, EEG, CSF and blood tests
were normal. The polysomnography and multiple sleep
latency test (MSLT) ﬁndings are summarized in Table 1.
She underwent use of antidepressants, lithium, and thior-
idazine without success. Carbamazepine up to 1200 mg/
day rendered the normalization of sleep. Attempts of dose
reduction resulted in attacks (the last in 2013). Nowadays
she is 23 y.o.able 1 – Neurophysiological characteristics of the cases
uring sleep attack).
Case 1 Case 2
olysomnography
fﬁciency (%) 95 51
leep latency (min) 3 5
EM latency (min) 100 71
1 (%) 2 5.5
2 (%) 63 50
3 (%) 13 36
EM (%) 22 8.5
rousals (per hour) o10 25
espiratory events (per hour) o5 16
SLTa
leep latency (min) 4 2
OREMPsb 3 2
Multiple sleep latency test.
Sleep onset REM period. Case 2: a 14 y.o. Caucasian boy had undetermined fever for
7 days. Since then he presented sudden sleepiness for 3–9
days, awakening for 2 h a day with confusion, marked
hunger and sexual disinhibition. During intervals he slept
normally and remembered the attacks as dreams. Physical
examination, brain CT and blood tests were normal.
Table 1 shows the polysomnographic and MSLT ﬁndings.
Treatments with antidepressants, methylphenidate,
divalproate and carbamazepine were unsuccessful. Ris-
peridone 1 mg/day decreased the frequency and duration
of attacks. With 1.5 mg/day the episodes ceased, except
during discontinuation in 2013. He returned to risperidone
and is 21 y.o. at present, free of sleep attacks since 2013.3. Discussion
Due to the rarity of RH, there are no trials providing ther-
apeutic guides [12]. Treatment evidence is based on empirical
use provided by case reports and series of cases. Carbama-
zepine [5,13], valproic acid [14], antipsychotics [1], lithium
[1,2], amphetamines [1], acetazolamide [15], and clarithromy-
cin [16] are the drugs that were described to be helpful for
normalizing sleep cycles in cases of KLS. When clearly
menstrual-related, RH may also be treated with oral contra-
ceptives [5].
The heterogeneity of response to medications is remark-
able from the reports, because no speciﬁc drug obtains
success in more than circa 40% of cases [1]. This suggests
that the mechanisms underlying RH are complex and that
hypothalamic dysfunction may be an epiphenomenon, part
of a process generated by processes affecting more wide-
spread central neurotransmission [11]. In this setting, the
assessment of HLA-DQB1n0602 and of CSF hypocretin levels
in all RH patients would be an interesting endeavor in terms
of physiopathologic investigation [4,8]. However, these ana-
lyses are not ordinarily performed due to logistical
unavailability.
An interesting issue regarding our reported cases is the fact
that MSLT accomplished during the sleep attacks revealed at
least two sleep onset REM periods (SOREMPs) and very short
sleep latency, suggesting that these ﬁndings are not pathog-
nomonic of narcolepsy, as previously stated [17,18].
The prognosis of RH, especially of KLS, is not as benign as
previously stated [3]. This reinforces the necessity of more
studies devoted to RH, not only for the elucidation of its
physiopathology, but also for guiding speciﬁc therapeutic
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